WaveMan
WaveMan · Company
PRGO · Perrigo Co Plc
> Search tickers & screens ⌘K
LIVE
← All companies

PRGO Perrigo (PRGO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001585364
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
197
13F, latest reported quarter
Conversions, 180 days
25
Codes C/M, not in net · $1.8M priced

Perrigo insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for PERRIGO Co plc in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Parker Geoffrey M.
Director
BUY
2025-11-14 SECtraded 2025-11-12
7,500
$106.3K
+22.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Aug 18, 2025.
  • -9.2% median (-11.8% mean) 90-day return after 5 previous buys.
  • The trade is 43.2% of the 17,375 shares held after it.
  • No other insider bought within 30 days.
  • 197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Parker Geoffrey M. bought about $106.3K of PRGO on Nov 12, 2025, the largest insider purchase at the company since 2024; 197 funds added in the latest 13F quarter.
Lennox Abigail
EVP and CSO
BUY
2025-09-10 SECtraded 2025-09-08
1,255
$28.1K
-26.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 1,255 shares held after it.
  • 4 other insiders bought within 30 days.
  • 197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP and CSO Lennox Abigail bought about $28.1K of PRGO on Sep 8, 2025; 4 other insiders bought within 30 days and 197 funds added in the latest 13F quarter.
Atkinson Charles
EVP, General Counsel & Sec.
BUY
2025-09-09 SECtraded 2025-09-05
1,000
$23.2K
-25.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 1,000 shares held after it.
  • 5 other insiders bought within 30 days.
  • 197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, General Counsel & Sec. Atkinson Charles bought about $23.2K of PRGO on Sep 5, 2025; 5 other insiders bought within 30 days and 197 funds added in the latest 13F quarter.
Willis Robert
EVP & CHRO
BUY
2025-08-22 SEC
1,488
$35.9K
-29.4%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Mar 1, 2024.
  • +4.6% median (+4.8% mean) 90-day return after 3 previous buys.
  • The trade is 3.5% of the 41,939 shares held after it.
  • 5 other insiders bought within 30 days.
  • 197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & CHRO Willis Robert bought about $35.9K of PRGO on Aug 22, 2025; 5 other insiders bought within 30 days and 197 funds added in the latest 13F quarter.
Parker Geoffrey M.
Director
BUY
2025-08-20 SECtraded 2025-08-18
4,375
$100.5K
-28.3%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on May 12, 2025.
  • -2.6% median (-4.7% mean) 90-day return after 4 previous buys.
  • The trade is 44.3% of the 9,875 shares held after it.
  • 5 other insiders bought within 30 days.
  • 197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Parker Geoffrey M. bought about $100.5K of PRGO on Aug 18, 2025, the largest insider purchase at the company since 2024; 5 other insiders bought within 30 days and 197 funds added in the latest 13F quarter.
46 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 41 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
197 funds bought in last quarter
more than 90% of Pharma & Biotech
Revenue
-2.8% year over year
below 60% of Pharma & Biotech
Margin
-33.5% net margin
more than 54% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
17.6% of the float short (float per yahoo 2026-10-26) · 7.2 days to cover · settled 2026-09-30
more than 91% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch PRGO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-22.8%12M
-56%-37%-17%+2%2025-102025-122026-022026-042026-062026-082026-10 2025-11-12 · Parker Geoffrey M. bought $106.3K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PRGO: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
22,703,127 sh
$235.9M
NEUBERGER BERMAN GROUP LLC
10,680,100 sh
$111.0M
VANGUARD PORTFOLIO MANAGEMENT LLC
9,045,661 sh
$94.0M
STATE STREET CORP
8,528,704 sh
$88.7M
FULLER & THALER ASSET MANAGEMENT, INC.
7,498,227 sh
$77.9M

Congress trades in PRGO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PRGO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

PRGO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco High Yield Equity Dividend AchieversTM ETF
$38.7M position · as of 2026-07-31
3.4%
Invesco Pharmaceuticals ETF
$11.6M position · as of 2026-07-31
2.4%
Invesco S&P SmallCap High Dividend Low Volatility ETF
$1.4M position · as of 2026-05-31
1.9%
PROFUND VP PHARMACEUTICALS
$158.6K position · as of 2026-06-30
1.4%
Global X SuperDividend U.S. ETF
$10.8M position · as of 2026-07-31
1.4%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$212.6K position · as of 2026-07-31
1.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2020
$11.0M
$7.9M
$2.7M
-12%
+11%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 197 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PRGO financials

Revenue growth
-2.8%
XBRL, annual
Net margin
-33.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.1B
four quarters, 2025-06-29 to 2026-06-27
Net margin, TTM
-41.9%
net income over revenue, 2025-06-29 to 2026-06-27
Free cash flow, TTM
$119.3M
operating cash flow minus capex, 2025-06-29 to 2026-06-27
Debt to equity
1.31x
long-term 2026-06-27 plus current 2026-06-27; equity 2026-06-27
Cash flow to debt
0.06x
TTM operating cash flow over long-term 2026-06-27 plus current 2026-06-27
Return on equity
-49.6%
TTM net income over average of 2025-06-28 and 2026-06-27
Return on assets
-19.6%
TTM net income over average of 2025-06-28 and 2026-06-27
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-20.1%
operating income (EBIT proxy) over average of 2025-06-28 and 2026-06-27 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$5.1B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-27 plus current 2026-06-27, minus cash 2025-09-27
FCF yield
+5.4%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$4.3B$4.4B$4.7B$4.5B
Gross profit$1.5B$1.5B$1.7B$1.5B
Operating income-$1.1B$112.9M$151.9M$78.9M
Net income-$1.4B-$171.8M-$12.7M-$140.6M
EPS (diluted)-10.29-1.25-0.09-1.04
Operating cash flow$238.5M$362.9M$405.5M$307.3M
Cashn/a$558.8M$751.3M$600.7M
Long-term debt$3.6B$3.6B$3.6B$4.1B
Buybacksn/an/an/a$0
Dividends paid$159.3M$152.5M$149.7M$142.4M
SEC XBRL, fiscal years, as known on 2026-10-28

PRGO Stock Sonar score 5/7 axes

Find similar shapesCompare

PRGO ranks highest on profitability (64th percentile) and institutional and government (55th), and lowest on risk and compliance (13th), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
64
Inputs
  • Return on equity-49.6% · 54 pct, sector of 545
  • Return on assets-19.6% · 67 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-20.1% · 73 pct, sector of 576
Financial health
44
Inputs
  • Debt to equity1.31x · 14 pct, sector of 352
  • Cash flow to debt0.06x · 75 pct, sector of 371
Growth
40
Inputs
  • Revenue growth, YoY-2.8% · 40 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
55
Inputs
  • Funds adding, latest quarter197 · 90 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$110K · 21 pct, sector of 133
Risk and compliance
13
Inputs
  • Short interest, % of float+17.6% · 20 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5y0.24 per $1B · 7 pct, universe of 1,048
  • New text in Risk Factors, latest 10-K+22.4% · 13 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies